Tier 4 — mechanistic

Balancing NAD + deficits with nicotinamide riboside: therapeutic possibilities and limitations

Cercillieux A, Ciarlo E, Canto C
Cellular and molecular life sciences : CMLS 2022 79; 8; 463

Bibliography

PubMed
PMID 35918544
PubMed Central
PMC9345839
DOI
10.1007/s00018-022-04499-5
Funding
Funding details are not specified in the accessible publication information.
Competing interests
Three authors were employees of Nestlé Research.

Study snapshot

DesignNarrative evidence review
ModelPublished mechanistic and clinical literature
SamplePreclinical and clinical NR literature
InterventionReview of NAD+ deficits and NR-based strategies
DurationPublished 2022 review
EndpointsEvidence synthesis and translational limitations

What the study showed, in plain terms

The review examined NR biology, translation and why clinical outcomes often differ from the more favorable mouse findings.

Key findings

The review examined NR biology, translation and why clinical outcomes often differ from the more favorable mouse findings.

What this study can and cannot tell us

Mechanistic plausibility and disease-model rescue are not a pooled clinical effect or proof of benefit in NAD+-replete people.

Related papers in the corpus

Tier 4
Emerging strategies, applications and challenges of targeting NAD + in the clinic
Zhang J et al. · Nature aging · 2025
Tier 4
What is really known about the effects of nicotinamide riboside supplementation in humans
Damgaard MV et al. · Science advances · 2023
Tier 4
Dietary Supplementation With NAD+-Boosting Compounds in Humans: Current Knowledge and Future Directions
Freeberg KA et al. · The journals of gerontology. Series A, Biological sciences and medical sciences · 2023
Tier 4
NAD + Precursors in Human Health and Disease: Current Status and Future Prospects
Yaku K et al. · Antioxidants & redox signaling · 2023
Tier 1
Effects of NAD+ precursor supplementation on glucose and lipid metabolism in humans: a meta-analysis
Zhong O et al. · Nutrition & metabolism · 2022
Tier 4
Preclinical and clinical evidence of NAD + precursors in health, disease, and ageing
Reiten OK et al. · Mechanisms of ageing and development · 2021

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology